Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maha Hussain

Showing results (161-170 of 213) with videos related to

Pageof 22
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 16, 2023
Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS TrialMaha Hussain, Bertrand Tombal, Fred Saad, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 17, 2021
A Randomized Phase II Study of Androgen Deprivation Therapy with or without Palbociclib in RB-positive Metastatic Hormone-Sensitive Prostate CancerPhillip L Palmbos, Stephanie Daignault-Newton, Scott A Tomlins, et al.
Investigational New Drugs|March 26, 2010
Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: a randomized phase II trial by the prostate cancer clinical trials consortiumDeborah A Bradley, Stephanie Daignault, Charles J Ryan, et al.
Cancer|November 20, 2013
Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinomaPetros D Grivas, Stephanie Daignault, Scott T Tagawa, et al.
The New England Journal of Medicine|September 21, 2020
Survival with Olaparib in Metastatic Castration-Resistant Prostate CancerMaha Hussain, Joaquin Mateo, Karim Fizazi, et al.
The New England Journal of Medicine|April 29, 2020
Olaparib for Metastatic Castration-Resistant Prostate CancerJohann de Bono, Joaquin Mateo, Karim Fizazi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 5, 2024
Radiographic Progression-Free Survival and Clinical Progression-Free Survival as Potential Surrogates for Overall Survival in Men With Metastatic Hormone-Sensitive Prostate CancerSusan Halabi, Akash Roy, Larysa Rydzewska, et al.
The Lancet. Oncology|July 23, 2013
Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trialDavid I Quinn, Catherine M Tangen, Maha Hussain, et al.
European Journal of Cancer (Oxford, England : 1990)|June 30, 2026
Clinically relevant endpoints and quality-of-life outcomes with darolutamide in patients with metastatic hormone-sensitive prostate cancer: Analyses of the phase III ARASENS trialKarim Fizazi, Matthew R Smith, Maha Hussain, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 1, 2022
Olaparib Efficacy in Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1, BRCA2, or ATM Alterations Identified by Testing Circulating Tumor DNANobuaki Matsubara, Johann de Bono, David Olmos, et al.
Pageof 22

Showing results (161-170 of 213) with videos related to

Sort By:
Pageof 22
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 16, 2023
Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS TrialMaha Hussain, Bertrand Tombal, Fred Saad, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 17, 2021
A Randomized Phase II Study of Androgen Deprivation Therapy with or without Palbociclib in RB-positive Metastatic Hormone-Sensitive Prostate CancerPhillip L Palmbos, Stephanie Daignault-Newton, Scott A Tomlins, et al.
Investigational New Drugs|March 26, 2010
Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: a randomized phase II trial by the prostate cancer clinical trials consortiumDeborah A Bradley, Stephanie Daignault, Charles J Ryan, et al.
Cancer|November 20, 2013
Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinomaPetros D Grivas, Stephanie Daignault, Scott T Tagawa, et al.
The New England Journal of Medicine|September 21, 2020
Survival with Olaparib in Metastatic Castration-Resistant Prostate CancerMaha Hussain, Joaquin Mateo, Karim Fizazi, et al.
The New England Journal of Medicine|April 29, 2020
Olaparib for Metastatic Castration-Resistant Prostate CancerJohann de Bono, Joaquin Mateo, Karim Fizazi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 5, 2024
Radiographic Progression-Free Survival and Clinical Progression-Free Survival as Potential Surrogates for Overall Survival in Men With Metastatic Hormone-Sensitive Prostate CancerSusan Halabi, Akash Roy, Larysa Rydzewska, et al.
The Lancet. Oncology|July 23, 2013
Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trialDavid I Quinn, Catherine M Tangen, Maha Hussain, et al.
European Journal of Cancer (Oxford, England : 1990)|June 30, 2026
Clinically relevant endpoints and quality-of-life outcomes with darolutamide in patients with metastatic hormone-sensitive prostate cancer: Analyses of the phase III ARASENS trialKarim Fizazi, Matthew R Smith, Maha Hussain, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 1, 2022
Olaparib Efficacy in Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1, BRCA2, or ATM Alterations Identified by Testing Circulating Tumor DNANobuaki Matsubara, Johann de Bono, David Olmos, et al.
Pageof 22